

**Preferred Drug List Committee
Meeting Agenda, Open Session
September 9, 2020 11:30am to 1:00pm**

Meeting Location*

*Due to COVID-19, this meeting will be held virtually. Please use the information below to join the meeting: Public Dial: (833) 713-0101; Conference ID: 8284514; Passcode: 7762323

WebEx: <https://intercall.webex.com/intercall/j.php?MTID=mbf4cb3ffa81a6adcc79fe32c5ebb45ae>

Please note: Audio is disabled on the WebEx. Audio will only be available on the Public Dial.

Members of the public are required to complete a conflict of interest form if they intend to provide public comments to the Committee. To assist the operator in coordinating public comment, completed forms are due 1 week prior to the meeting (September 2, 2020). Please email the completed form to Annette.Grant@ks.gov.

Committee Members

Jessica Bates, PharmD., BCPS (Chair)
Emily Blew, PharmD.
Taylor Gill, PharmD., BCPS
Katherine Grimsley, M.D.
Robert Haneke, Pharm.D.

Megan Hedden, PharmD.
William Pankey, M.D.
James Rider, D.O.
Donna Sweet, M.D.
Wayne Wallace, M.D.

KDHE-DHCF Staff

Annette Grant, RPh
Victor Nguyen, Pharm.D.

DXC Technology Staff

Karen Kluczykowski, RPh.
Harry Vu, PharmD

Kathy Kaesewurm, RN, BSN

- I. Call to Order
 - a. Announcements and Introductions
- II. Review & Approval of Meeting Minutes from 03/11/2020
- III. Old Business
 - a. Consent Agenda Items
 - i. PDL New Drug Placements
 - 1. Licart™ Patch
 - 2. Lyumjev™ Injection
 - 3. Ortikos™ Capsules
 - 4. Rybelsus® Tablets
 - ii. Committee discussion/Recommendations

IV. New Business

a. New Drug Classes

- i. COPD Agents- Triple Therapy: (Breztri Aerosphere™, Trelegy Ellipta)
 1. Public Comment
 2. Committee Discussion/Recommendations
- ii. Colony Stimulating Factors – Filgrastim Products: (Granix®, Neupogen®, Nivestym™, Zarxio®)
 1. Public Comment
 2. Committee Discussion/Recommendations
- iii. Colony Stimulating Factors – Pegfilgrastim Products: (Fulphila®, Neulasta®, Neulasta® Onpro®, Udenyca®, Ziextenzo®)
 1. Public Comment
 2. Committee Discussion/Recommendations
- iv. Migraine – Acute Treatment Agents: (Nurtec™ ODT, Reyvow™, Ubrelvy™)
 1. Public Comment
 2. Committee Discussion/Recommendations
- v. Opioid Dependence Agents: (Bunavail, Naltrexone Tablets, Probuphine®, Sublocade™, Suboxone®, Subutex, Vivitrol®, Zubsolv®)
 1. Public Comment
 2. Committee Discussion/Recommendations

b. New Drugs to Existing Classes

- i. Acne Agents- Topical- Antibiotics: (Amzeeq™)
 1. Public Comment
 2. Committee Discussion/Recommendations
- ii. Acne Agents- Topical Retinoids: (Aklief®)
 1. Public Comment
 2. Committee Discussion/Recommendations
- iii. Ankylosing Spondylitis Agents: (Taltz®)
 1. Public Comment
 2. Committee Discussion/Recommendations
- iv. CGRP Receptor Antagonists: (Vyepti™)
 1. Public Comment
 2. Committee Discussion/Recommendations
- v. Sleep Agents- Scheduled- Non-Benzodiazepine: (Dayvigo™)
 1. Public Comment
 2. Committee Discussion/Recommendations

- vi. Rosacea Agents- Topical: (Zilxi™)
 - 1. Public Comment
 - 2. Committee Discussion/Recommendations

V. Open Public Comment

VI. Adjourn

****THIS AGENDA IS SUBJECT TO CHANGE****